Tennessee SB0436 amends state codes to integrate biosimilar medicines into existing drug frameworks, ensuring they are treated similarly to reference.
Tennessee SB0436 amends various sections of Tennessee Code Annotated to incorporate biosimilar medicines into the state's drug frameworks. This includes adding "or biosimilars" to relevant subsections and ensuring health carriers, health benefit plans, and utilization review organizations do not require patients to try biosimilars before covering the equivalent branded prescription drug. The changes aim to eliminate barriers to accessing biosimilar medicines and the savings they can provide.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.